Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by longterm56on Aug 08, 2019 6:12pm

135 Views

Post# 30008618

RE:RE:RE:TH Regains Control Over Distribution RightsEGRIFTA Worldwide

Can you describe your logic for "confirms that they are indeed in discussions" ? What I want to know is why the other companies gave up their rights "for no cost" if this was some big win.

-LT

palinc2000 wrote: I think this confirms that they are indeed in discussions with or in preparation to enter negotiations with a big pharma to outlicense Egrifta worldwide or a takeover or something in between

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal